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Recent studies suggest that peritoneal CD4þ T lymphocytes
may control recruitment of polymorphonuclear leukocytes
(PMN) during peritonitis by an interleukin-17
(IL-17)-dependent mechanism. IL-17 and granulocyte
colony-stimulating factor (G-CSF) have been proposed to
form an axis that regulates PMN transmigration. Here we
report on the role of G-CSF released by human peritoneal
mesothelial cells (HPMCs) in IL-17A-mediated peritoneal PMN
accumulation. In vitro exposure of HPMCs to IL-17A resulted
in a time- and dose-dependent release of G-CSF. This effect
was related to the induction of G-CSF mRNA and mediated
through the nuclear factor-jB (NF-jB) pathway. The novel
observation was that IL-17A-stimulated NF-jB activation in
HPMCs followed a biphasic profile, with an early induction
(45 min), followed by the return to basal levels (90 min), and a
delayed induction (3 h). Tumor necrosis factor a
synergistically amplified IL-17A-induced G-CSF production by
enhanced NF-jB activation and through stabilization of
G-CSF mRNA. Intraperitoneal (i.p.) administration of IL-17A in
Balb/c mice resulted in increased local levels of G-CSF and
selective PMN accumulation. Administration of anti-G-CSF
blocking antibody before IL-17A injection significantly
reduced the IL-17A-triggered PMN infiltration. This effect
occurred despite increased i.p. levels of PMN-specific
chemokines KC and macrophage inflammatory protein-2
seen in animals treated with anti-G-CSF antibody. These data
demonstrate that the mesothelium-derived G-CSF plays an
important role in IL-17A-induced PMN recruitment into the
peritoneum.
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Over the past few years increasing evidence has been
accumulating to suggest that interleukin-17 (IL-17) cytokines
play an important role in immunity (see references1,2 for
recent reviews). IL-17A (initially known as IL-17) is a
prototype and best characterized member of this cytokine
family. It is secreted mainly by activated CD4þ T
lymphocytes, and recent studies have established that IL-
17-producing cells develop via a unique TH cell lineage
distinct from TH1 and TH2 subsets.
3,4 In contrast to restricted
expression of IL-17A, its receptor is distributed ubiquitously.
IL-17A is viewed as a proinflammatory cytokine because of
its ability to induce many key mediators of inflammation.
Interestingly, IL-17A appears to be involved particularly in
responses mediated by polymorphonuclear neutrophils
(PMN). In vitro studies have demonstrated that IL-17A
stimulates many types of structural non-immune cells to
release neutrophil chemoattractants, including CXC chemo-
kine ligand (CXCL)1 (growth-related oncogene a), CXCL6
(granulocyte chemotactic protein-2), and CXCL8 (IL-8)
(summarized in5). The administration of IL-17A or the
adenovirus-mediated IL-17A overexpression in mice results
in the induction of neutrophil-targeting chemokines and
subsequent neutrophil infiltration.6,7 Accordingly, the ani-
mals deficient in either IL-17A or IL-17 receptor exhibit
decreased chemokine expression in tissues and reduced
neutrophil recruitment during inflammatory and immune
reactions.8 Importantly, the lack of IL-17A signalling is
associated with ineffective neutrophil response to bacterial
(Klebsiella pneumoniae), fungal (Candida albicans), or
parasite (Toxoplasma gondii) burden, and reduced animal
survival.8–10
In addition to stimulating chemokine secretion, IL-17A
promotes granulopoiesis (reviewed in11). This effect is related
largely to the induction of granulocyte colony-stimulating
factor (G-CSF) and stem cell factor. In vitro, IL-17A
stimulates G-CSF production by fibroblasts, colonic myofi-
broblasts, and bronchial epithelial cells.12–16 In vivo, inter-
leukin-17 receptor knockout mice display reduced G-CSF
expression in response to infection.8 Interestingly, animals
deficient in leukocyte adhesion molecules have peripheral
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neutrophilia that correlates with increased levels of
both IL-17 and G-CSF.17–19 Therefore, it has been hypothe-
sized that IL-17A and G-CSF form a regulatory feedback
loop that regulates peripheral neutrophil numbers and
migration.17,19
The significance of IL-17A in host defence has been
best characterized in pulmonary inflammation.1 It appears
that IL-17A may play an equally important role in the
peritoneum. Most IL-17A in mice is expressed in the
mesenteric lymph nodes.19 In rats IL-17A was found to
mediate host protection during sepsis induced by cecal
ligation and puncture.20 On the other hand, development
of intra-abdominal adhesions and abscesses after experi-
mental injury or infection in mice was associated with the
peritoneal accumulation of IL-17-producing T cells.21,22 As in
other tissues, IL-17A acted then to induce neutrophil-
recruiting chemokines. Both the neutralization of IL-17 and
the blockade of the CXC chemokine receptor type 2
significantly reduced adhesion formation.22 We have pre-
viously identified peritoneal mesothelial cells as the most
likely source of IL-17-induced chemokines.23 As peritoneal
mesothelial cells are also capable of producing G-CSF,24 in
the current study we have examined the effect of IL-17A on
mesothelial cell G-CSF production in vitro. We demonstrate
that IL-17A, acting via nuclear factor-kB (NF-kB) pathway,
strongly stimulates G-CSF synthesis in mesothelial cells.
Moreover, our pilot in vivo experiments hint at a significant
role of G-CSF in IL-17A-induced neutrophil accumulation in
the peritoneum.
RESULTS
In vitro studies
Unstimulated human peritoneal mesothelial cells (HPMCs)
released only trace amounts of G-CSF. Exposure to IL-17A
resulted in a time- and dose-dependent increase in G-CSF
secretion (Figure 1a and b). With IL-17A at a dose of 50 ng/
ml this increase became significant above the control level
after 6 h of incubation and continued to rise over the next
48 h. Analysis of the G-CSF secretion rate (calculated by
dividing the net chemokine release during each experimental
period by the number of hours of the respective time
interval) revealed that the most pronounced IL-17A-driven
G-CSF release occurred within the first 24 h. Statistically
significant stimulation of G-CSF secretion was achieved with
IL-17A at a dose of 1 ng/ml and above. An anti-IL-17
antibody specifically blocked IL-17A-induced G-CSF produc-
tion, which fell nearly to basal levels (Figure 1c).
Increased release of G-CSF by IL-17A-treated HPMCs was
associated with a time-dependent induction of G-CSF mRNA
with the maximal expression observed after 6 h (Figure 1d).
Pretreatment of HPMCs with the transcription inhibitor
actinomycin D, at doses that did not affect cell viability (not
shown), led to a reduction in both G-CSF mRNA expression
(Figure 1e), and G-CSF protein release (Figure 1f).
Stimulation of HPMCs with IL-17A resulted in an
increased NF-kB DNA binding. As visualized by electro-
phoretic mobility shift assay (EMSA), the profile of NF-kB
activation was clearly biphasic, increasing rapidly within
15 min, reaching the maximum after 45 min, then returning
to basal levels at 90 min, and peaking again at 3 h (Figure 2a).
These data were further confirmed with the TransAMTM NF-
kB Family Kit, which identified NF-kB subunits activated
(Figure 2b). Both peaks showed a similar pattern of p50, p65,
and p52 activation. They differed, however, in the involve-
ment of c-Rel and RelB, activation of which was maximal
after 45 and 180 min, respectively. Exposure to IL-17A led
also to a transient expression of inhibitory protein kB (IkB)a,
one of the target genes activated by NF-kB. Expression of
IkBa mRNA reached the maximum at 90 min and then
subsided (Figure 3). In order to modulate NF-kB activation,
cells were treated with MG-132, an inhibitor of IkBa
degradation. Preliminary experiments determined that a 4-
h exposure to MG-132 at doses up to 10 mM did not impair
viability of HPMCs (data not shown). During this period
MG-132 decreased dose dependently IL-17A-induced G-CSF
mRNA expression (Figure 4).
Exposure of HPMCs to tumor necrosis factor (TNF)a
resulted in a modest dose-dependent increase in G-CSF
release. When TNFa was combined with IL-17A, however, the
secretion of G-CSF was highly above the levels generated by
each stimulus alone and significantly above the predicted
additive values. This effect depended on both the dose of IL-
17A and TNFa (Figure 5a and b). The most potent effect was
exerted by a combination of 10 ng/ml IL-17A and 1 ng/ml
TNFa, which triggered G-CSF release exceeding 7–9 times the
expected additive values. In experiments examining the effect
of sequential addition of TNFa and IL-17A on G-CSF
secretion, HPMCs were incubated in the presence or absence
of TNFa or IL-17A for 24 h then washed and cultured again
for further 24 h in the presence or absence of the cytokines
(Figure 5c). These experiments revealed that some priming
with individual cytokines occurred. HMPCs pretreated with
TNFa secreted more G-CSF in response to IL-17A compared
with cells not exposed to TNFa. Similar effect was evident
when the cytokines were applied in a reversed order.
However, the magnitude of these effects was significantly
less in comparison to when IL-17A and TNFa were added
simultaneously.
Exposure to TNFa increased IL-17A-induced G-CSF
mRNA expression in a dose-dependent manner (Figure 6a).
Moreover, the presence of TNFa enhanced NF-kB DNA
binding (Figure 6b and c). Under conditions that did not
affect cell viability, the treatment with MG-132 decreased G-
CSF mRNA expression in a dose-dependent manner (Figure
6d). Furthermore, the actinomycin D chase experiments
showed that the combination of IL-17A together with TNFa
considerably delayed the degradation of G-CSF mRNA
compared to IL-17A alone (Figure 7).
IL-17A was also found to stimulate HPMCs proliferation
(Figure 8). The effect was dose dependent with maximum
stimulation (13478% of the control) achieved with 1 ng/ml
of IL-17A.
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In vivo studies
As demonstrated previously,23 intraperitoneal (i.p.) admin-
istration of IL-17A in mice resulted in a time-dependent
influx of leukocytes into the peritoneal cavity. This leukocyte
infiltrate consisted almost exclusively of PMN, which were
nearly absent from the normal peritoneum. The accumula-
tion of PMN peaked at 4 h and then gradually subsided
(Figure 9a). Specificity of the effect was previously confirmed
by the administration of IL-17A together with an anti-IL-17A
neutralizing antibody, which significantly reduced PMN
recruitment.23 The assessment of lavage fluid for G-CSF
revealed a marked increase in its levels with maximal
concentrations observed 2–4 h after IL-17A administration
(Figure 9b). Administration of an anti-G-CSF neutralizing
antibody before IL-17A injection reduced the IL-17A-
triggered PMN infiltration within 4 h by 83.076.1%, whereas
no significant effect was observed in response to the
unspecific control antibody (Figure 9c). As the IL-17A-
mediated PMN influx was shown to depend partially on
preceding chemokine KC and macrophage inflammatory
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Figure 1 | Characterization of IL-17A-induced G-CSF release by HPMCs. (a) Quiescent HPMCs were exposed to either control medium (J)
or 50 ng/ml IL-17A (K) for specified times. (b) HPMCs were stimulated with increasing doses of IL-17A for 24 h. Data were obtained from (a) six
and (b) nine experiments with cells from separate donors. Asterisks represent a statistically significant difference compared to the unstimulated
controls. (c) HPMCs were incubated for 24 h with 25 ng/ml IL-17A in the presence of either neutralizing anti-IL-17 antibody or control IgG (both
at 1 mg/ml). Data are the mean of seven separate experiments. An asterisk represents a statistically significant inhibition. (d) HPMCs were
treated with IL-17A (100 ng/ml) for the times indicated. G-CSF mRNA expression was analyzed by RT-PCR. Results are representative of three
separate experiments. (e) HPMCs were incubated with actinomycin D (0.5 mg/ml) for 3 h in the presence or absence of IL-17A (100 ng/ml). G-CSF
mRNA expression was analyzed by RT-PCR. Results are representative of two separate experiments. (f) HPMCs were pretreated with increasing
doses of actinomycin D for 30 min, washed with culture medium and then stimulated with IL-17A (50 ng/ml) for 24 h. G-CSF release was
measured by ELISA. Data are the mean of six separate experiments. An asterisk represents a statistically significant inhibition.
516 Kidney International (2007) 71, 514–525
o r i g i n a l a r t i c l e J Witowski et al.: Role of G-CSF in IL-17A-mediated peritoneal neutrophil recruitment
protein (MIP)-2 induction, we measured the i.p. concentra-
tions of these chemokines, which peaked within 1 h after IL-
17A administration. The levels of both KC and MIP-2 in
animals given anti-GSF antibody were significantly increased
compared to animals treated with either IL-17A alone or IL-
17A and control antibody (Figure 9d).
DISCUSSION
It is now believed that one of the key functions of IL-17
cytokines is to provide a link between T cells and
inflammation and thereby between adaptive and innate
immunity. IL-17A appears to be involved particularly in
neutrophil-dominated responses and as such plays an
important role in host defence,1,5 Recent studies clearly
demonstrate that, by stimulating local cells to produce
chemokines and granulopoietic factors, IL-17A acts as a
potent promoter of neutrophil production and chemotaxis.
Gene microarray analyses in human bronchial epithelial cells,
osteoblasts, and fibroblasts have shown that out of many
genes involved in the inflammatory reaction, those encoding
G-CSF and CXC family chemokines were most dramatically
upregulated by IL-17A.3,15,25 Accordingly, the decreased
expression of CXC chemokines and G-CSF receptor was
detected in synovial explants from interleukin-17 receptor-
deficient mice.26
We have previously demonstrated that IL-17A is a potent
inducer of CXCL1 (growth-related oncogene a) in HPMCs.23
In this study, we show that HPMCs respond to IL-17A also
by producing G-CSF. The release of G-CSF by HPMCs
stimulated with IL-17A was clearly time and dose dependent,
with effective IL-17A concentrations similar to those seen in
other in vitro studies. Specificity of the effect was confirmed
by the inhibition of G-CSF release with the anti-IL-17-
neutralizing antibody. The stimulatory effect of IL-17A on G-
CSF synthesis occurred at the transcriptional level as
evidenced by a time-dependent induction of G-CSF mRNA
and the inhibition of IL-17A-driven G-CSF release by
actinomycin D. Similar induction of G-CSF expression and
secretion in response to IL-17A was observed in murine
fibroblasts12 and human airway epithelial cells.15,16 In
contrast, IL-17A induced only a weak release of G-CSF in
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Figure 2 | Activation of the NF-jB pathway in HPMCs by IL-17A. Quiescent HPMCs were stimulated with IL-17A (100 ng/ml). At indicated
intervals, nuclear extracts were prepared and NF-kB activation was monitored either by (a) EMSA or by (b) TransAMTM assay. Results are
representative for two separate experiments.
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Figure 3 | Effect of IL-17A on IjBa mRNA expression in HPMCs.
HPMCs were stimulated with IL-17A (100 ng/ml) for the times
indicated. The expression of NF-kB-inducible gene, IkBa was analyzed
with RT-PCR. Results of a representative experiment of two
performed.
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Figure 4 | Inhibition of IL-17A-induced G-CSF in HPMCs by MG-
132. Quiescent HPMCs were stimulated with IL-17A (100 ng/ml) in
the presence or absence of MG-132 at doses indicated. Exposure to
MG-132 began 30 min before stimulation. After 3 h of incubation the
expression of G-CSF mRNA was assessed by RT-PCR. Results of a
representative experiment of two performed.
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human colonic myofibroblasts14 and did not have any effect
at all in human lung microvascular endothelial cells.27 In
both cell systems, however, IL-17A did amplify the stimula-
tory effect of other proinflammatory cytokines.
Exposure of HPMCs to IL-17A resulted in a rapid NF-kB
activation as demonstrated by both classic EMSA and new
TransAMTM technique. Activation of NF-kB by IL-17A has
been observed in several cells types including macrophages,28
chondrocytes,29 synovial fibroblasts,30 intestinal epithelial
cells,31 and pancreatic and colonic myofibroblasts.14,32,33 For
the first time, however, we have observed that the process of
IL-17A-induced NF-kB activation followed a biphasic
pattern. It consisted of an ‘early’ peak seen within 45 min, a
return to basal levels after 90 min, and a ‘late’ induction after
3 h. The bimodal profile of NF-kB activation has been found
to occur in a cell type-dependent manner in response to such
stimuli as lipopolysaccharide, IL-1, and TNFa.34 A detailed
analysis by Schmidt et al.35 revealed that the biphasic pattern
of NF-kB activation is regulated by a complex interplay
between mitogen-activated protein kinase kinase (MEKK)
kineases and IkB. It appears that the early phase is mediated
by MEKK3 and IkBa, whereas MEKK2 and IkBb are involved
in a delayed NF-kB activation. Degradation of IkBa allows
translocation of NF-kB to the nucleus and subsequent
activation of target genes. These include IkBa itself, and as
a result the re-synthesized IkBa protein terminates the NF-kB
response.36 Indeed, in HPMCs treated with IL-17A we
observed a typical rapid induction of the IkBa mRNA.
Phosphorylation and degradation of IkBa protein, and
subsequent induction of IkBa mRNA in response to IL-17A
was also seen in osteoarthritic chondrocytes37 and glioblas-
toma cell lines.38 The biological significance of biphasic NF-
kB activation is not well understood. It has been hypothe-
sized that it may underlie an effective control of the
inflammatory reaction.34 Interestingly, we have observed that
although the two peaks were similar with respect to the
activation of classic NF-kB subunits p50 and p65, they
differed in the activation of RelB and c-Rel. Relatively little is
known about the function of these subunits. RelB was shown
to act as a suppressor of transcription controlling the
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Figure 5 | Effect of a combination of IL-17A and TNFa on G-CSF release by HPMCs. (a) Cells were exposed to control medium or TNFa (1 ng/
ml) in the presence of increasing doses of IL-17A. (b) Alternatively cells were exposed to control medium or IL-17A (10 ng/ml) in the presence of
increasing doses of TNFa. After a 24-h incubation, the supernatants were assayed for G-CSF by ELISA. Data were derived from seven separate
experiments. Asterisks represent statistically significant differences compared to the calculated additive values. (c) HPMCs were incubated in
the presence or absence of IL-17A (10 ng/ml) and TNFa (1 ng/ml) for 24 h (stimulus 1), washed and incubated again for 24 h in the presence or
absence of the cytokines (stimulus 2). G-CSF concentrations were measured by ELISA and expressed as fold-increases above control levels
(0.670.2 pg/mg cell protein). Data were derived from six independent experiments.
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expression of proinflammatory mediators in fibroblasts.39 c-
Rel appears to play an important role in cell proliferation and
has been implicated in many human cancers.40
MG-132 is a proteasome inhibitor and as such prevents
the degradation of IkBa and blocks the NF-kB activation.
The inhibition of IL-17A-induced G-CSF mRNA expression
and protein release by MG-132 may point to the involvement
of NF-kB in this response, although one cannot exclude that
the effect of MG-132 is more complex. It is now clear that
proteasomal degradation not only relieves NF-kB of IkBa
inhibition, but may also significantly modulate the activity of
other molecules involved in NF-kB signalling.41 Previous
studies have demonstrated that NF-kB proteins can activate
the G-CSF promoter in cells exposed to IL-1 or TNFa.42 In
some cell types the response of the G-CSF promoter may
require the interaction of NF-kB proteins with other
transcription factors.42,43 In this respect, Shen et al.44 have
recently identified common transcription factor binding site
patterns in IL-17 target promoters. They demonstrated that
the in a subgroup of genes the IL-17-induced transcription
could be mediated through coordinated activation of NF-kB
and CCAAT/enhancer binding protein. Their analysis
indicated that G-CSF might belong to this category.
It has been consistently observed in many cell systems that
IL-17A synergizes with TNFa in cytokine production. We
have found that exposure of HPMCs to IL-17A and TNFa
resulted in a synergistic rise in G-CSF release. The magnitude
of this synergy seemed to be even greater than of that
recorded previously in bronchial epithelial cells.15 The
mechanism underlying the interaction between IL-17A and
TNFa is not entirely clear and may depend on the cell type
involved and the cytokine produced. The synergistic genera-
tion of G-CSF by HPMCs appeared to be partially mediated
by the NF-kB pathway as evidenced by increased NF-kB
DNA binding and the inhibitory effect of MG-132. The
involvement of NF-kB has also been implicated in the
synergistic effects of IL-17A and TNFa in colonic myofibro-
blasts,32 osteoblast-like osteosarcoma cells,45 and rheumatoid
synovial fibroblasts.46 In contrast, Ruddy et al.47 have
demonstrated that the CCAAT/enhancer binding protein d
rather than NF-kB is the direct target of the combined signal
in osteoblastic cell line.
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Figure 6 | Regulation of G-CSF expression in HPMCs treated with a combination of IL-17A and TNFa. (a) Quiescent HPMCs were exposed
for 3 h to IL-17A together with increasing doses of TNFa. G-CSF mRNA expression was analyzed by RT-PCR. Lane 1: control medium, lane 2:
IL-17A (100 ng/ml), lane 3: TNFa (1 ng/ml), lane 4: IL-17A (100 ng/ml)þ TNFa (10 ng/ml), lane 5: IL-17A (100 ng/ml)þ TNFa (1 ng/ml), lane 6:
IL-17A (100 ng/ml)þ TNFa (0.1 ng/ml); (b) NF-kB DNA binding activity in HPMCs exposed for 60 min to IL-17A and TNFa. Lane 1: unstimulated
control, lane 2: IL-17A (100 ng/ml), lane 3: IL-17A (100 ng/ml)þ TNFa (1 ng/ml). (c) NF-kB p50 binding activity as quantified by TransAMTM assay.
Experimental conditions were as in (b). Results of a representative experiment of two performed. (d) HPMCs were stimulated with a
combination of IL-17A (100 ng/ml) and TNFa (1 ng/ml) in the presence of increasing doses of MG-132. After 3 h of incubation the expression of
G-CSF mRNA was assessed by RT-PCR.
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Another mechanism proposed to mediate IL-17A and
TNFa synergy is stabilization of cytokine transcripts. The 30-
untranslated region of the G-CSF mRNA contains two
distinct destabilizing elements, which suggests that the
expression of G-CSF can also be regulated through the
control of mRNA stability.48 Indeed, we have found that IL-
17A cooperates with TNFa to enhance stability of G-CSF
mRNA in HPMCs. We have previously observed a similar
effect with regard to the stability of the CXCL1 (growth-
related oncogene a) transcript in HPMCs.23 Enhanced
mRNA stability in response to the combination of IL-17A
and TNFa has also been associated with synergistic
upregulation of IL-6 and CXCL8 (IL-8) in colonic and
pancreatic myofibroblasts, and osteoblasts.32,49–51 These
studies have also shown that stabilization of these transcripts
by IL-17A and TNFa is largely regulated through p38
mitogen-activated protein kinase cascade.
Our in vitro experiments also revealed that IL-17A
stimulated HPMCs proliferation. The effect of IL-17A on
cell growth appears to be cell type dependent. IL-17A was
found to stimulate the proliferation of lymphocytes,52
mesenchymal stem cells,53 and airway epithelial cells.54 In
contrast, it inhibited the growth of intestinal epithelial
cells.31,55 It did not have a direct effect on endothelial cells,
but modulated the stimulatory impact of other vascular
growth factors.56,57
Results of in vivo studies suggest that induction of G-CSF
is an important element mediating the involvement of IL-
17A in inflammation. The coordinated action of IL-17A, IL-
23, and G-CSF has been proposed to form a link between
localized inflammatory response and granulopoiesis.11,19 In
this respect, the induction of G-CSF by IL-17A has been
primarily viewed as a means of securing sustained neutrophil
proliferation in response to infection. However, G-CSF
appears to act also directly in the inflamed tissue and exert
more immediate effects. In order to determine whether our
in vitro observations on the rapid induction of G-CSF by IL-
17A may bear any significance for the peritoneal cavity in
vivo, recombinant murine IL-17A was injected i.p. in wild-
type Balb/c mice. As expected, this resulted in peritoneal
neutrophil accumulation.23 Moreover, it induced a significant
rise in i.p. levels of G-CSF, which reached its maximum
within 4 h after injection. When, however, the activity of G-
CSF was neutralized with the blocking antibody, the IL-17A-
driven i.p. neutrophilia at this time point was reduced to the
level induced by the vehicle alone. The short time period
during which this effect became observable, suggested that
the activity of G-CSF was crucial for early stages of
neutrophil recruitment rather than for the stimulation and
proliferation of granulocyte precursors. We have previously
demonstrated that the PMN influx in response to IL-17A
could be partially blocked by neutralization of neutrophil-
specific chemokines KC and MIP-2.23 We have therefore
measured the i.p. levels of these chemokines, when they
peaked 1 h after injection of IL-17A. In contrast to our
expectations, the concentrations of KC and MIP-2 were
significantly increased in animals treated with anti-G-CSF
antibody. It means that despite higher levels of PMN-
attracting chemokines, these animal displayed decreased
accumulation of PMN in tissues. It may indicate that
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Figure 8 | Effect of IL-17A on HPMCs proliferation. HPMCs were
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G-CSF operates at a different level and when its effect is
abolished by anti-G-CSF antibody, a compensatory increase
in chemokines occurs. Recent in vivo studies in mice deficient
in either G-CSF or G-CSF receptor showed diminished
responsiveness of neutrophils to chemokines and increased
PMN apoptosis in the absence of G-CSF signalling.58,59 It is
well known that G-CSF delays clearance of neutrophils from
the inflammatory site by inhibiting their apoptosis.60,61 In
turn, phagocytosis of apoptotic PMN was proposed to fuel
IL-17 production and subsequent granulopoiesis.19 There-
fore, one may hypothesize that in our setting neutralization
of G-CSF resulted in enhanced generation of endogenous IL-
17 with a resultant increase in chemokine production. This
issue requires further detailed studies. The complexity of the
problem is exacerbated by the fact that there are several other
potential mechanisms whereby G-CSF may affect the number
of mature neutrophils at the site of inflammation. They
include increased neutrophil adhesion to endothelial cells62,63
and subsequent transendothelial migration,64,65 increased
expression of chemokine receptors on neutrophils,66 and
increased chemotactic response to chemokines.58 Moreover,
G-CSF appears to be able to induce the expression of specific
neutrophil chemoattractants in neutrophils themselves, as
exemplified by of CXCL7 (ENA78).67 The fact that G-CSF
exerts simultaneously multiple effects on neutrophils may
explain why its neutralization reduced IL-17A-induced PMN
accumulation almost to control levels. Interestingly, the
blockade of a related molecule, granulocyte-macrophage
colony-stimulating factor, abolished the accumulation of
neutrophils in the airways induced by IL-17A and TNFa.68
Although IL-17A is generated by cells associated with
adaptive immunity, it appears to promote innate immune
responses. By doing so, IL-17A may enhance faster and more
effective recruitment of PMN after a repeated encounter with
pathogen.69 Interestingly, it has been suggested that also G-
CSF may act as a factor linking innate and adaptive
immunity by modulating the function of T cells and
dendritic cells.70 On the other hand, excessive IL-17A activity
may result in neutrophil-mediated tissue injury. Experimen-
tal evidence suggests that such a scenario may occur during
peritonitis.21,22 Our data indicate that the IL-17A-driven
release of G-CSF from mesothelial cells may be an element of
the peritoneal inflammatory response.
MATERIALS AND METHODS
Materials
Unless indicated otherwise, all chemicals were purchased from
Sigma-Aldrich (St Louis, MO, USA). Recombinant cytokines and
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Figure 9 | Regulation of IL-17A-induced peritoneal neutrophil infiltration by G-CSF. (a) Mice were i.p. administered with 1 mg mouse IL-17A
(K) or vehicle (PBS,J). At defined time points, PMN infiltration was assessed using differential cell counting; (b) G-CSF levels were quantified
by ELISA. Results are expressed as the mean obtained from four to nine animals per condition. Asterisks represent significant differences
compared to the controls at the same time point. (c) Mice were first injected with either anti-mouse G-CSF neutralizing antibody or irrelevant
control IgG, and then administered with mouse IL-17A or PBS. The number of PMN in the peritoneal cavity was determined 4 h later. Data were
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anti-cytokine antibodies were obtained from R&D Systems (Wies-
baden, Germany), stored in aliquots at 701C and freshly thawed
for each experiment. All reagents were of tissue culture or molecular
biology grade, as required. According to the manufacturers, the
endotoxin level in these materials was o0.1 ng/mg protein for
cytokines and o0.1 ng/ml for media and buffers. MG-132, a
selective proteasome inhibitor, was purchased from Biomol (Ply-
mouth Meeting, PA, USA) and dissolved in dimethyl sulfoxide. All
tissue culture plastics were from Nunc (Roskilde, Denmark).
Peritoneal mesothelial cell culture
HPMCs were isolated from the specimens of omentum obtained
from consenting patients undergoing elective abdominal surgery.
Cells were isolated, characterized, and cultured as described in detail
elsewhere.71,72 Before experiments, cells were rendered quiescent by
serum deprivation for 48 h. HPMCs were stimulated at 371C as
specified in the figure legends. In experiments with MG-132, control
cells received an equivalent dose of the solvent (0.2% v/v dimethyl
sulfoxide). Cell viability was assessed with the 3-(4,5-dimethyl-
thiazolyl-2)-2,5-diphenyltetrazolium bromide test, as described
previously.73 Culture supernatants were harvested, centrifuged to
remove cellular debris, and stored at 701C until assayed. All
stimulations were performed with cells no older than the second
passage to minimize the number of senescent cells.
Animal studies
The experiments were performed on male Balb/c inbred
mice weighing 25–30 g (Institute of Occupational Medicine,
Lo´dz, Poland). Animals were housed under 12-h light/dark cycles
and fed ad libitum with standard chow. The experiments
were performed as described previously23 and according to the
guidelines of the Committee for Animal Studies at University
Medical School, Poznan˜, Poland. Briefly, recombinant mouse IL-17A
was diluted in sterile endotoxin-free phosphate-buffered saline
(PBS) (Dulbecco’s PBS, PAA Laboratories GmbH, Linz, Austria) and
administered i.p. at a dose of 1 mg/mice in a total volume of 500ml.
Control animals received an equivalent volume of PBS alone. For
the procedure the animals were put under brief ether anesthesia and
then allowed to recover. In separate experiments the animals were
first given an i.p. injection of 200 ml PBS containing 1 mg of either
anti-mouse G-CSF neutralizing antibody or unspecific control IgG,
followed by infusion of 300 ml PBS containing 1 mg IL-17A. At
designated time points the animals were anesthetized, killed by
bleeding, and the peritoneal cavity was lavaged with 2.5 ml PBS
containing 3 mM ethylenediaminetetraacetic acid. Leukocyte re-
trieved were assessed by differential cell counting and cytokine
concentrations were quantified by enzyme-linked immunosorbent
assay (ELISA).
Cytokine measurements
Concentrations of human and mouse G-CSF, as well as of mouse KC
and MIP-2, were measured using DuoSets Immunoassays (R&D
Systems) according to the manufacturer’s instructions. G-CSF
concentrations in HPMCs culture supernatants were quantified in
pg/ml and normalized per cellular protein and expressed as pg/mg
cell protein. Total cellular protein was determined according to the
method of Bradford using Bio-Rad Protein Assay Dye Reagent (Bio-
Rad, Munich, Germany) and used as a parameter reflecting cell
number. One microgram of HPMCs protein was found to
correspond to (mean7s.d.) 2.171.0 103 cells (n¼ 16).
RNA isolation and analysis
Total RNA from HPMCs cultures was extracted with the RNA
Bee (Tel-Test, Friendswood, TX, USA) and purified according
to the manufacturer’s protocol. One microgram of RNA was
reverse transcribed into cDNA with random hexamer primers,
as described.74 Expression of target mRNAs was assessed by
PCR as summarized below. Sequences of primers for human
G-CSF were kindly provided by Stratagene (Amsterdam, The
Netherlands). PCR products were separated by electrophoresis in
ethidium bromide stained 3% agarose gels and visualized under UV
illumination.
Primer sequences and PCR conditions
Monitoring NF-jB activation
Activation of the transcription factor NF-kB was detected
with EMSA and further characterized with the use of the
TransAMTM NF-kB Family Kit (Active Motif, Carlsbad, CA,
USA). For EMSA, cells were harvested at different time points
after stimulation and nuclear extracts were prepared accord-
ing to the method of Dignam et al.78 A double-stranded
oligonucleotide containing the NF-kB consensus sequence
(50-AGTTGAGGGGACTTTCCCAGGC-30; Promega, Man-
nheim, Germany) was end labelled with 32P-dATP (specific
activity 3000 Ci/mmol; Amersham Biosciences, Freiburg,
Germany) using T4 polynucleotide kinase (Promega) and
purified from unincorporated radioactivity with Sephadex
G25 spin columns (Pharmacia, Heidelberg, Germany).
Binding reactions were performed for 15 min at room
temperature in a total volume of 25 ml containing
5 104 c.p.m. of the labelled probe and 5 mg nuclear protein
Sequence
Product
size (bp)
PCR
cycles
Annealing
temperature (1C) Reference
G-CSF
F: 50-GTGCAGGAA
GCCACCCCCCTGGGC-30
471 34 67 15
R: 50-CCCTCCTGCC
CGGCCCTGGAAAGC-30
IkBa
F: 50-ACTCGTTCCT
GCACTTGGCC-30
237 26 60 75
R: 50-CCCTCCTGCC
CGGCCCTGGAAAGC-30
a-Actin
F: 50-GGAGCAATG
ATCTTGATCTT-30
204 30 55 76
R: 50-TGCTCACAGG
CAAGGTGTAG-30
b-Actin
F: 50-ATCCCCCAA
AGTTCACAA-30
147 30 55 77
R: 50-CTGGGCCA
TTCTCCTTAG-30
G-CSF, granulocyte colony-stimulating factor; IkBa, inhibitory protein kB; PCR,
polymerase chain reaction.
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in 20 mM N-2-hydroxyethylpiperazine-N0-2-ethanesulphonic
acid (pH 7.9), 50 mM KCl, 5 mM dithiothreitol, 1 mM
ethylenediaminetetraacetic acid, 1 mM MgCl2, 2mg poly(dI-
dC)poly(dC-dI), 100 mM phenylmethylsulfonyl fluoride, and
4% glycerol. Competition experiments were performed in the
presence of a 100-fold molar excess of the unlabelled probe.
DNA–protein complexes were electrophoresed in 4% non-
denaturing polyacrylamide/Tris-borate-ethylenediaminete-
traacetic acid gels at 160 V for 2 h at 41C. The gels were
fixed in 10% methanol/10% acetic acid, dried, and exposed
to Kodak X-ray films and analyzed by phosphoimaging (Fujix
Bas II phosphoimager, Fuji).
In the TransAMTM procedure nuclear extracts were
incubated with an immobilized NF-kB consensus site
and the NF-kB subunits bound were detected with
specific antibodies. The specificity of the assay was confirmed
by competitive inhibition with the wild type and
mutated consensus oligonucleotides provided. The whole
assay was performed according to the manufacturer’s
instructions.
Proliferation studies
HPMCs proliferation was measured by [3H]-thymidine
incorporation, as described.73 Briefly, cells in the exponential
phase of growth were synchronized by serum deprivation for
24 h and then stimulated with increasing doses of IL-17A,
and finally pulsed with [3H]-thymidine (1 mCi/ml; Institute
of Radioisotopes, Prague, Czech Republic) for 24 h. The cells
were then lysed and the released radioactivity was measured
in a beta liquid scintillation counter (Wallac, Perkin Elmer,
Warsaw, Poland).
Statistical analysis
Data are presented as means7s.e.m. Numbers (n) for all in
vitro data refer to the number of experiments performed with
cells isolated from different donors. Statistical analyses were
performed using GraphPad PrismTM 4.00 software (GraphPad
Software Inc., San Diego, CA, USA). The data were compared
with repeated measures analysis of variance with New-
man–Keuls modification. A P-value of less than 0.05 was
considered significant.
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